S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
NASDAQ:MTP

Midatech Pharma - MTP Stock Forecast, Price & News

$0.67
-0.04 (-5.63%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.67
$0.74
50-Day Range
$0.49
$0.78
52-Week Range
$0.38
$1.95
Volume
76,304 shs
Average Volume
124,368 shs
Market Capitalization
$13.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
MTP stock logo

About Midatech Pharma (NASDAQ:MTP) Stock

Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Midatech Pharma Price Performance

Shares of MTP Stock opened at $0.71 on Tuesday. Midatech Pharma has a fifty-two week low of $0.38 and a fifty-two week high of $1.95. The company has a debt-to-equity ratio of 0.06, a current ratio of 6.39 and a quick ratio of 6.39. The stock's 50-day simple moving average is $0.62 and its 200-day simple moving average is $0.76.

Receive MTP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Midatech Pharma and its competitors with MarketBeat's FREE daily newsletter.

MTP Stock News Headlines

Midatech Pharma PLC News
Midtech Booms on Discovery
Stock Alert: Midatech Pharma Jumps 40%
Midatech Pharma PLC Announces Business Update
Midatech Pharma PLC Announces Launch of new website
See More Headlines
Receive MTP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Midatech Pharma and its competitors with MarketBeat's FREE daily newsletter.

MTP Company Calendar

Today
8/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MTP
Fax
N/A
Employees
18
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$800,000.00
Book Value
$1.13 per share

Miscellaneous

Free Float
N/A
Market Cap
$13.19 million
Optionable
Not Optionable
Beta
2.34

Key Executives

  • Mr. Stephen A. Stamp (Age 60)
    CEO, CFO, Company Sec. & Director
    Comp: $278k
  • Dr. Dmitry Zamoryakhin M.D. (Age 42)
    Chief Scientific Officer
    Comp: $275.15k
  • Dr. Daniel Palmer MBA
    Ph.D., VP of Technology
  • Dr. Tim Sparey Ph.D.
    Chief Bus. Officer
  • Mr. Justin Barry BSc (Hons.)
    MBIOL, CBIOL, QP, Head of Manufacturing
  • Mr. David Benharris (Age 57)
    Pres of Midatech Pharma US Inc
  • Ms. Fiona Sharp
    Group Financial Controller













MTP Stock - Frequently Asked Questions

How has Midatech Pharma's stock performed in 2022?

Midatech Pharma's stock was trading at $1.05 at the beginning of the year. Since then, MTP stock has decreased by 33.3% and is now trading at $0.70.
View the best growth stocks for 2022 here
.

Are investors shorting Midatech Pharma?

Midatech Pharma saw a drop in short interest during the month of July. As of July 15th, there was short interest totaling 36,300 shares, a drop of 44.8% from the June 30th total of 65,800 shares. Based on an average daily trading volume, of 206,700 shares, the days-to-cover ratio is currently 0.2 days.
View Midatech Pharma's Short Interest
.

What other stocks do shareholders of Midatech Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Midatech Pharma investors own include CRISPR Therapeutics (CRSP), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), Vaxart (VXRT), Nabriva Therapeutics (NBRV), Novavax (NVAX), Plug Power (PLUG), SCYNEXIS (SCYX), Sangamo Therapeutics (SGMO) and Sorrento Therapeutics (SRNE).

What is Midatech Pharma's stock symbol?

Midatech Pharma trades on the NASDAQ under the ticker symbol "MTP."

Who are Midatech Pharma's major shareholders?

Midatech Pharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include Great Valley Advisor Group Inc. (0.25%).

How do I buy shares of Midatech Pharma?

Shares of MTP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Midatech Pharma's stock price today?

One share of MTP stock can currently be purchased for approximately $0.70.

How much money does Midatech Pharma make?

Midatech Pharma (NASDAQ:MTP) has a market capitalization of $13.78 million and generates $800,000.00 in revenue each year.

How many employees does Midatech Pharma have?

Midatech Pharma employs 18 workers across the globe.

How can I contact Midatech Pharma?

Midatech Pharma's mailing address is ODDFELLOWS HOUSE 19 NEWPORT ROAD, CARDIFF X0, CF24 0AA. The official website for the company is www.midatechpharma.com. The company can be reached via phone at 441235888300 or via email at ir@midatechpharma.com.

This page (NASDAQ:MTP) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.